On February 16, 2022, FDA posted a compounding danger warn describing the likely pitfalls associated with at-property use of compounded ketamine nasal spray and several adverse occasion studies. The February 2022 compounding risk alert also provided details about Spravato, that is subject matter to your Hazard Evaluation and Mitigation Strategy (RE… Read More